Shawn Seamans, Chief Commercial Officer, CoverMyMeds | Authors | Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking ...

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can ...

A crash course on the bubble itself, including therapeutic areas most affected. This column marks the first of a six-part series on “Popping the Gross-to-Net (GTN) Bubble" in the pharmaceutical ...

Embedding access tools at prescribing reduces manual enrollment, portal switching, and late activation, enabling faster ...

Pharmaceutical Commerce | Journals | Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking approved drugs to market.

Brent Wilhelm of Cencora discusses why available inventory still leads to shortages, and how tighter distributor-manufacturer integration and AI could close the gap. In part 1 of a 3-part interview ...

Consideration totals up to $7.0B ($3.25B upfront; up to $3.75B milestones), with expected close in 2H 2026 and customary regulatory approvals required. iGPS uses engineered lentiviral-based particles ...

PwC's Roel van den Akker says pharma M&A ran beyond expectations in the first half of 2026, with dealmaking potentially on pace to hit $300 billion in H2. Pharmaceutical Commerce recently checked in ...

West Asia–North Africa represented $1.75 billion of India’s FY25 pharma exports, dominated by finished dosage forms plus biosimilars and vaccines, with the UAE, Iraq, Egypt, and Saudi Arabia leading.

Supreme Court inaction leaves intact lower-court rulings rejecting takings and compelled-speech theories against “fair price” designations in Medicare price negotiation. Courts emphasized ...

In today’s Pharma Pulse, the FDA unveils a Plausible Mechanism framework to fast-track ultra-rare disease therapies, while Astellas partners with Vir Biotechnology in a massive $2.1 billion oncology ...